Filter by
Format
All
Sort by
Newest

Metabolic

  • Empagliflozin
  • Linagliptin
  • Empagliflozin + Linagliptin
/ph/metabolic/empagliflozin/cv-risk-protection/emprise-rwe-updates-ada-2020

EMPRISE RWE updates from ADA 2020
/ph/metabolic/empagliflozin/efficacy/how-slow-down-progression-kidney-disease

How to slow down the progression of Kidney Disease
/ph/metabolic/empagliflozin/efficacy/unlocking-crm-link-t2d

59:54
Unlocking The CRM link in T2D
/ph/metabolic/empagliflozin/empa-reg-outcome-trial/recorded-webinar-jardiance-video-demandprof-darren

43:34
Recorded Webinar for Jardiance Video On Demand_Prof. Darren McGuire
/ph/metabolic/empagliflozin/guidelines/phmore-80-guidelines-worldwide-endorse-empagliflozin

PH_MORE THAN 80 GUIDELINES WORLDWIDE ENDORSE EMPAGLIFLOZIN (JARDIANCE)_Infographic
/ph/metabolic/empagliflozin/efficacy/prof-carvalho-discussing-cv-death-reduction-empa-reg

1:16
Prof. Carvalho discussing CV Death reduction in EMPA-REG
/ph/metabolic/empagliflozin/efficacy/defining-high-risk-and-very-high-risk-patients-t2d

1:41
Defining HIGH risk and VERY HIGH risk patients with T2D
/ph/metabolic/empagliflozin/efficacy/reduce-risk-cv-death-t2d-patients-high-cv-risk

1:40
Reduce the risk of CV death for T2D patients with high CV risk
/ph/metabolic/empagliflozin/efficacy/empagliflozin-jardiance-reduced-risk-hospitalisation-heart

Empagliflozin (Jardiance ) reduced the risk in hospitalisation for heart failure
/ph/metabolic/empagliflozin/efficacy/prof-davies-her-ee-video-question-2-engaged-cardio

0:58
Prof Davies on her EE video Question 2 for Engaged Cardio
/ph/metabolic/empagliflozin/efficacy/passive-cardio-cv-safe-not-enoughee-prof-davies

1:11
Passive Cardio CV Safe is not Enough_EE Prof Davies
/ph/metabolic/empagliflozin/efficacy/ee-video-prof-melanie-davies-defining-high-very-high-risk

1:34
EE Video Prof. Melanie Davies defining High & Very High risk patients
/ph/metabolic/empagliflozin/cv-risk-protection/empagliflozins-early-impact-cv-death-reduction

Empagliflozin's early impact in CV Death Reduction
/ph/metabolic/empagliflozin/cv-risk-protection/t2d-cvd-risk-equivalent

T2D is a CVD risk equivalent
/ph/metabolic/empagliflozin/efficacy/jardiance-gives-you-power-accomplish-more-providing-multiple

Jardiance gives you the power to accomplish more by providing multiple benefits
/ph/metabolic/empagliflozin/cv-risk-protection/empagliflozin-near-us-insights-its-use-asians

Empagliflozin near to us: Insights from its use in Asians
/ph/metabolic/empagliflozin/cv-risk-protection/empagliflozin-clinical-endorsement-revolutionising

Empagliflozin's clinical endorsement: Revolutionising guidelines across specialties
/ph/metabolic/empagliflozin/empa-reg-outcome-trial/empagliflozin-cv-indication-wave-change-across

Empagliflozin CV indication : A wave of change across the world
/ph/metabolic/empagliflozin/empa-reg-outcome-trial/empa-reg-outcome-breakthrough-trial-type-2

EMPA-REG OUTCOME: A Breakthrough trial in Type 2 Diabetes
/ph/metabolic/empagliflozin/efficacy/how-empagliflozin-jardiance-differs

01:59
How Empagliflozin (Jardiance®) differs from other SGLT2 inhibitors
/ph/metabolic/empagliflozin/efficacy/empagliflozin-allows-you-protect-patients

01:47
Empagliflozin allows you to protect patients from CV risks/death
/ph/metabolic/empagliflozin/cv-risk-protection/defining-established-cvd

10:19
Defining Established CVD
/ph/metabolic/empagliflozin/cv-risk-protection/seeing-through-cv-risk-continuum

53:47
Seeing through the CV Risk Continuum: How Empagliflozin benefits patients across the spectrum
/ph/metabolic/empagliflozin/guidelines/t2d-cvd-risk-equivalent

T2D is a CVD risk equivalent
/ph/metabolic/empagliflozin/guidelines/definition-very-high-risk-patients-esc-2019-guidelines

05:13
Definition of very high risk patients as per ESC 2019 Guidelines
/ph/metabolic/empagliflozin/guidelines/2019-esc-guidelines

2019 ESC Guidelines
/ph/metabolic/empagliflozin/experts-interview/asian-cardiodiabetes-dr-mansoor-husain

03:51
Asian CardioDiabetes Forum 2018 - The role of a cardiologist in diabetes management - Dr. Mansoor Husain
/ph/metabolic/empagliflozin/experts-interview/asian-cardiodiabetes-dr-neale-cohen

03:48
Asian CardioDiabetes Forum 2018 - How have recent CV outcome trials influence clinical practice by Dr. Neale Cohen
/ph/metabolic/empagliflozin/experts-interview/asian-cardiodiabetes-prof-richard-donnelly

02:24
Asian CardioDiabetes Forum 2018 - Why is it important to examine evidence and not assume class effect by Prof. Richard Donnelly
/ph/metabolic/empagliflozin/experts-interview/asian-cardiodiabetes-forum-2018-dr-mansoor-husain

Asian CardioDiabetes Forum 2018 - The role of a cardiologist in diabetes management - Dr. Mansoor Husain (transcript)
/ph/metabolic/empagliflozin/experts-interview/asian-cardiodiabetes-forum-2018-dr-neale-cohen

Asian CardioDiabetes Forum 2018 - How have recent CV outcome trials influence clinical practice by Dr. Neale Cohen (transcript)
/ph/metabolic/empagliflozin/experts-interview/asian-cardiodiabetes-forum-2018-prof-richard-donnelly

Asian CardioDiabetes Forum 2018 - Why is it important to examine evidence and not assume class effect by Prof. Richard Donnelly (transcript)
/ph/metabolic/empagliflozin/experts-interview/impact-ada-easd-consensus--dr-alice-cheng

01:47
Impact of ADA/EASD Consensus Guidelines on T2D management by Dr. Alice Cheng
/ph/metabolic/empagliflozin/experts-interview/impact-ada-easd-consensus--prof-mark-cooper

01:21
Impact of ADA/EASD Consensus Guidelines on T2D management by Prof. Mark Cooper
/ph/metabolic/empagliflozin/cv-risk-protection/emprise-empagliflozin-real-world-effectiveness

EMPRISE - Empagliflozin Real World Effectiveness
/ph/metabolic/empagliflozin/prescribing-information/empagliflozin-metformin-hci-jardiance-duo

Empagliflozin Metformin HCI (Jardiance Duo®) Prescribing Information
/ph/metabolic/jardiance-empagliflozin/empa-reg-outcome-trial/randomised-controlled-trials-vs-real-world

Randomised Controlled Trials vs Real World Evidence
/ph/metabolic/empagliflozin/empa-reg-outcome-trial/influence-empa-reg-outcome-trial-results-t2d

02:01
The influence of the EMPA-REG Outcome trial results on T2D management
/ph/metabolic/empagliflozin/cv-risk-protection/what-are-main-considerations-when-choosing-medication

02:35
What are the main considerations when choosing a medication for patients with type 2 diabetes?
/ph/metabolic/empagliflozin/cv-risk-protection/are-patients-t2d-elevated-cv-risk

02:10
Are patients with T2D at elevated CV risk?
/ph/metabolic/empagliflozin/empa-reg-outcome-trial/empa-reg-outcome-study-result

EMPA-REG Outcome study result
/ph/metabolic/empagliflozin/cv-risk-protection/empagliflozin-risk-reduction-cv-death

02:44
Reduction in CV death
/ph/metabolic/empagliflozin/cv-risk-protection/what-leading-cause-death-patients-type-2-diabetes

01:22
What is the leading cause of death in patients with type 2 diabetes?
/ph/metabolic/linagliptin/simplicity/simplicity-trajenta

39:49
Simplicity of Trajenta
/ph/metabolic/linagliptin/efficacy/linagliptin-efficacy-data

Linagliptin Efficacy Data
/ph/metabolic/linagliptin/simplicity/simplicity-believer-video-ted-wu

4:08
Simplicity Believer Video - Ted Wu
/ph/metabolic/linagliptin/simplicity/limited-kidney-video-roger-chen

6:35
Limited to Kidney Video - Roger Chen
/ph/metabolic/linagliptin/simplicity/trajenta-recorded-webinar-henrik-groop

59:50
Trajenta Recorded Webinar - Per Henrik Groop
/ph/metabolic/linagliptin/efficacy/linagliptin-efficacy-vs-other-dpp4i-fue

Linagliptin Efficacy vs Other DPP4i FUE
/ph/metabolic/linagliptin/cv-renal-safety/trajenta-cvot-infographic

Trajenta CVOT infographic
/ph/metabolic/linagliptin/cv-renal-safety/carmelina-cvot-video

1:50
Carmelina CVOT Video
/ph/metabolic/linagliptin/efficacy/simplicity

2:17
Simplicity
/ph/metabolic/linagliptin/efficacy/emperor-reduced-results-fuecardios

EMPEROR-Reduced RESULTS FUE_Cardios
/ph/metabolic/linagliptin/simplicity/pcdr-esteban-jodar-06-trajenta-ph-video

0:48
PC_Dr. Esteban Jodar 06 Trajenta PH Video
/ph/metabolic/linagliptin/simplicity/dr-esteban-jodar-07-carmelina-simplicity-trajenta-reinforced

0:31
Dr. Esteban Jodar 07 - With CARMELINA®, the simplicity of Trajenta® is reinforced by the reinforced safety profile, established efficacy and the convenience of one dose once daily
/ph/metabolic/linagliptin/cv-renal-safety/4q-trajenta-opd-video-sb-mark-cooper

2:24
4Q Trajenta OPD Video-SB-Mark Cooper
/ph/metabolic/linagliptin/cv-renal-safety/cv-and-kidney-safety-linagliptin-ina-asians-adc

CV and Kidney Safety of Linagliptin ina Asians ADC
/ph/metabolic/linagliptin/efficacy/linagliptin-efficacy-vs-other-dpp4i-adc

Linagliptin Efficacy vs Other DPP4i ADC
/ph/metabolic/linagliptin/simplicity/linagliptin-simplicity-and-convenience-adc

2:00
Linagliptin Simplicity and Convenience ADC
/ph/metabolic/linagliptin/cv-renal-safety/carolina-asian-subanalysis

Carolina Asian Subanalysis
/ph/metabolic/linagliptin/simplicity/simplifying-t2d-management-linagliptin-prof-alexander-tan

37:07
Simplifying T2D management with Linagliptin by Prof. Alexander Tan
/ph/metabolic/linagliptin/cv-renal-safety/carmelina-asian-subanalysis

CARMELINA Asian Subanalysis
/ph/metabolic/linagliptin/simplicity/simplifying-t2d-management-linagliptin-prof-henrik-groop

51:14
Simplifying T2D management with Linagliptin by Prof. Per-Henrik Groop
/ph/metabolic/linagliptin/simplicity/what-are-key-results-carmelina-carolina

2:19
What are the key results of CARMELINA/CAROLINA and why is it unique vs other DPP4i CVOTs?
/ph/metabolic/linagliptin/efficacy/linagliptin-dependable-efficacy

Linagliptin: Dependable efficacy in type 2 diabetes
/ph/metabolic/linagliptin/prescribing-information/linagliptin-metformin-hcl-trajenta-duo-prescribing

Linagliptin Metformin HCl (Trajenta Duo®) Prescribing Information
/ph/metabolic/linagliptin/prescribing-information/linagliptin-trajenta-prescribing-information

Linagliptin (Trajenta®) Prescribing Information
/ph/metabolic/empagliflozin-linagliptin/efficacy/glyxambi-advantage-vs-other-fdc

33:25
Advantage of Glyxambi over other FDC
/ph/metabolic/empagliflozin-linagliptin/safety/cardiovascular-renal-safety

Cardiovascular & Renal Safety
/ph/metabolic/empagliflozin-linagliptin/efficacy/2020-american-association-clinical-endocrinology

2020 American Association of Clinical Endocrinology Guidelines
/ph/metabolic/empagliflozin-linagliptin/efficacy/multiple-benefits-one-small-pill

Multiple Benefits in one small pill
/content/external-expert-video-glyxambis-unique-advantages

3:16
External Expert video on Glyxambi's unique advantages
/content/external-expert-video-early-intensive-treatment

2:47

External Expert video on Early Intensive Treatment
/ph/metabolic/empagliflozin-linagliptin/efficacy/professor-javier-ampudia-webinar-expanding

58:52
Professor Javier Ampudia Webinar “Expanding Treatment Options for Glycemic Reduction in Patients with T2DM: Role of Empagliflozin+Linagliptin Combination
/ph/metabolic/empagliflozin-linagliptin/efficacy/recorded-webinar-mark-cooper-last-july-1-2020

35:53
Recorded webinar of Mark Cooper last July 1, 2020
/ph/metabolic/empagliflozin-linagliptin/efficacy/early-glycemic-control-treating-t2d-patients

2:13
Early glycemic control in treating T2D patients
/ph/metabolic/empagliflozin-linagliptin/efficacy/single-powerful-combination-pill

2:51
A single powerful combination pill
/ph/metabolic/empagliflozin-linagliptin/mode-action/single-powerful-combination-pill

0:57
Prof. Cooper Complementary actions of SGLT2i+DPP4i
/ph/metabolic/empagliflozin-linagliptin/efficacy/slow-down-progression-t2d

1:21
Prof. Cooper Early Glycemic Control in T2D
/ph/metabolic/empagliflozin-linagliptin/efficacy/slow-intensification-and-treatment-will-lead-poor

00:00
Prof. Davies Wealth of Evidence in Early HbA1c control
/ph/metabolic/empagliflozin-linagliptin/efficacy/control-hba1c-early-phase

00:00
Prof. Carvalho Treat Early & Effectively
/ph/metabolic/empagliflozin-linagliptin/mode-action/when-consider-fixed-dose-combination-t2d

00:45
When to Consider Fixed Dose Combination in T2D
/ph/metabolic/empagliflozin-linagliptin/efficacy/rationale-using-dpp4i-sglt2i-fdc

01:46
Rationale of using a DPP4i+SGLT2i FDC
/ph/metabolic/empagliflozin-linagliptin/efficacy/patient-profile-glyxambi

01:11
Patient Profile of Empagliflozin + Linagliptin (Glyxambi®)
/ph/metabolic/empagliflozin-linagliptin/efficacy/advantage-glyxambi-versus-other-fdc-t2d-richard

00:55
Advantage of Empagliflozin + Linagliptin (Glyxambi®) versus other FDC in T2D
/ph/metabolic/empagliflozin-linagliptin/efficacy/advantage-glyxambi-versus-other-fdc-t2d-stephan

01:20
Advantage of Empagliflozin + Linagliptin (Glyxambi®) versus other FDC in T2D
/ph/metabolic/empagliflozin-linagliptin/efficacy/significance-achieving-glycemic-control-early

01:22
Significance of Achieving Glycemic Control Early

Cardiovascular

  • Dabigatran etexilate
/ph/cardiovascular/dabigatran-etexilate/safety/ph-re-dual-vs-augustus-infographic

PH_RE-DUAL_vs_AUGUSTUS_infographic
/ph/cardiovascular/dabigatran-etexilate/safety/re-dual-pci-subanalyses-qa-video-prof-stefan-hohnloser

2:30
RE-DUAL PCI subanalyses Q&A video with Prof Stefan Hohnloser - renal function
/ph/cardiovascular/dabigatran-etexilate/safety/re-dual-pci-subanalyses-qa-video-prof-ten-berg-age

3:15
RE-DUAL PCI subanalyses Q&A video with Prof Ten Berg - Age
/ph/cardiovascular/dabigatran-etexilate/safety/re-dual-pci-sub-analyses-qa-video-prof-ten-berg-pci

3:07
RE-DUAL PCI sub analyses Q&A video with Prof Ten Berg - PCI complexity
/ph/cardiovascular/dabigatran-etexilate/reversibility/praxbind-numbers-infographic-flashcard

Praxbind by the Numbers Infographic Flashcard
/ph/cardiovascular/dabigatran-etexilate/reversibility/importance-considering-reversibility-choice

03:27
Importance of considering reversibility in the choice of NOAC
/ph/cardiovascular/dabigatran-etexilate/safety/robust-data-both-doses-pradaxa

02:12
Robust data for both doses of Pradaxa
/ph/cardiovascular/dabigatran-etexilate/safety/low-dose-noacs-and-gi-bleeding

01:03
Low dose NOACs and GI Bleeding
/ph/cardiovascular/dabigatran-etexilate/safety/consistency-pradaxa-safety-data-rcts-rwes

02:42
Consistency of Pradaxa's Safety Data from RCTs to RWEs
/ph/cardiovascular/dabigatran-etexilate/spaf-webinars/stroke-prevention-af-patient-co-morbid

44:07
Stroke prevention in the AF Patient with co-morbid illnesses by Dr. Jan Steffel
/ph/cardiovascular/dabigatran-etexilate/safety/re-ly-asia

14:12
RE-LY Asia
/ph/cardiovascular/dabigatran-etexilate/efficacy/overview-re-ly-trial

02:45
Overview of RE-LY Trial
/ph/cardiovascular/dabigatran-etexilate/reversibility/innovations-dabigatran

01:22
Innovations of Dabigatran
/ph/cardiovascular/dabigatran-etexilate/safety/innovations-dabigatran

01:22
Innovations of Dabigatran
/ph/cardiovascular/dabigatran-etexilate/efficacy/innovations-dabigatran

01:22
Innovations of Dabigatran
/ph/cardiovascular/dabigatran-etexilate/about-disease/what-are-treatment-options-af

01:49
What are the treatment options for AF?
/ph/cardiovascular/dabigatran-etexilate/about-disease/what-atrial-fibrillation

01:37
What is Atrial Fibrillation?
/ph/cardiovascular/dabigatran-etexilate/about-disease/what-are-risk-factors-and-how-do-we-risk-stratify

02:31
What are the risk factors and how do we risk stratify?
/ph/cardiovascular/dabigatran-etexilate/about-disease/how-do-we-assess-bleeding-risk-prior-anticoagulation

00:50
How do we assess bleeding risk prior to anticoagulation?
/ph/cardiovascular/dabigatran-etexilate/safety/dr-hori-lecture-video-ethnic-difference-noac-trials

06:15
Dr Hori Lecture Video - Ethnic Difference in NOAC Trials
/ph/cardiovascular/dabigatran-etexilate/safety/asian-experience-dabigatran

05:41
The Asian experience with Dabigatran
/ph/cardiovascular/dabigatran-etexilate/safety/overview-re-ly-trial

02:45
Overview of RE-LY Trial
/ph/cardiovascular/dabigatran-etexilate/reversibility/john-knight-case-study

02:34
Testimony from a Stroke Patient: The John Knight Case Study
/ph/cardiovascular/dabigatran-etexilate/safety/safety-proven-rwe

03:38
Safety proven by RWE
/ph/cardiovascular/dabigatran-etexilate/safety/clinical-trials-real-world-evidence

03:34
From Clinical Trials to Real-World Evidence
/ph/cardiovascular/dabigatran-etexilate/safety/gloria-af-wealth-data-it-holds

02:55
GLORIA AF, the wealth of data it holds
/ph/cardiovascular/dabigatran-etexilate/dosage-administration/idarucizumab-praxbind-administration

02:39
Idarucizumab (Praxbind®) Administration Video
/ph/cardiovascular/dabigatran-etexilate/safety/low-dose-noac-usage-closer-look

Low-Dose NOAC Usage: A Closer Look
/ph/cardiovascular/dabigatran-etexilate/safety/us-department-defense-healthcare-database

03:33
US Department of Defense Healthcare Database
/ph/cardiovascular/dabigatran-etexilate/prescribing-information/idarucizumab-praxbind-prescribing

Idarucizumab (Praxbind®) Prescribing Information
/ph/cardiovascular/dabigatran-etexilate/prescribing-information/dabigatran-etexilate-prescribing

Dabigatran etexilate (Pradaxa®) Prescribing information
/ph/cardiovascular/dabigatran-etexilate/mode-action

02:20
Mode of Action of Idarucizumab (Praxbind®)

Oncology

  • Afatinib
/ph/oncology/giotrif/safety/use-afatinib-giotrif-elderly-patients

01:55
Use of Afatinib (Giotrif®) in Elderly Patients
/ph/oncology/giotrif/brain-metastasis/sequencing-patients-brain-metastases

01:30
Sequencing in Patients with Brain Metastases
/ph/oncology/giotrif/safety/will-dose-adjustment-compromise-treatment-efficacy-afatinib

02:20
Will Dose Adjustment Compromise Treatment Efficacy of Afatinib?
/ph/oncology/giotrif/efficacy/discussing-treatment-approach-patients

02:00
Discussing Treatment Approach with Patients
/ph/oncology/giotrif/sequencing/clinical-benefit-prolonged-chemo-free-interval

01:15
Clinical Benefit of Prolonged Chemo-Free Interval
/ph/oncology/giotrif/brain-metastasis/choice-egfr-tki-patients-brain-metastases-clinical-evidence

02:30
Choice of EGFR TKI in patients with brain metastases: Clinical Evidence with Afatinib
/ph/oncology/giotrif/sequencing/resistance-mechanisms-3rd-generation-tkis

01:35
Resistance Mechanisms to 3rd Generation TKIs
/ph/oncology/giotrif/efficacy/treatment-goal-1st-line-egfr-m-nsclc

03:25
Treatment Goal in 1st Line EGFR M+ NSCLC
/ph/oncology/giotrif/sequencing/sequencing-tkis-efgr-m-nsclc

02:25
Sequencing of TKIs in EFGR M+ NSCLC
/ph/oncology/giotrif/brain-metastasis/choice-egfr-tki-patients-brain-metastases-real-world-evidence

02:15
Choice of EGFR TKI in patients with brain metastases: Real-World Evidence
/ph/oncology/giotrif/sequencing/clonal-evolution-egfr-m-nsclc-implications-intherapeutic-sequencing

04:00
Clonal Evolution in EGFR M+ NSCLC: Implications inTherapeutic sequencing
/ph/oncology/giotrif/sequencing/giotag-real-world-evidence-asian-subgroup

01:35
GioTag Real-World Evidence: Asian subgroup
/ph/oncology/giotrif/efficacy/activity-egfr-tkis-nsclc-patients-brain-metastases

05:00
Activity of EGFR TKI's in NSCLC Patients with Brain Metastases
/ph/oncology/giotrif/sequencing/defining-optimal-tki-sequencing-patients-egfr-disease

35:10
Defining Optimal TKI Sequencing in EGFR M+ NSCLC: GioTag RWD Lecture by Professor Vera S. Hirsh, MD
/ph/oncology/giotrif/safety/realgido-real-world-study

RealGiDo - Real-world study on dose adjustment
/ph/oncology/giotrif-giotrif/giotrif-safety/realgido-real-world-data-tolerability-guided-dose-adjustment

21:05
Dose adjustment of Afatinib (Giotrif®): RealGiDo RWD Lecture by Professor Vera S. Hirsh, MD
/ph/oncology/giotrif/sequencing/giotag-real-world-study

GioTag: Real-world study on Afatinib (Giotrif®) followed by osimertinib in EGFR m+ NSCLC patients
/ph/oncology/giotrif/sequencing/optimising-outcomes

01:24
Optimising outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when?
/ph/oncology/giotrif/efficacy/singapore-real-world-data

Singapore Real World Data
/ph/oncology/giotrif/efficacy/south-korea-real-world-data

South Korea Real World Data
/ph/oncology/giotrif/prescribing-information

Afatinib (Giotrif®) Prescribing Information

Respiratory

  • Tiotropium + olodaterol
/content/ph-spiolto-inhaleability-slider-design-video-chapter-2

2:53
PH Spiolto Inhaleability Slider Design Video - Chapter 2
/ph/respiratory/spiolto/quality-life/ph-spiolto-inhaleability-slider-design-video-chapter-1

1:56
PH Spiolto Inhaleability Slider Design Video - Chapter 1
/ph/respiratory/spiolto/efficacy/spiolto-respimat-inhaleability-infographic-092020

Spiolto Respimat Inhaleability Infographic 092020
/ph/respiratory/spiolto/expert-videos/phdrusmani-v32020

3:09
PH_Dr.Usmani V3_2020
/ph/respiratory/spiolto/expert-videos/phdrusmani-v42020

13:14
PH_Dr.Usmani V4_2020
/ph/respiratory/spiolto/expert-videos/dr-omar-usmaniwhat-factors-contribute-low-pifr

7:22
Dr. Omar Usmani_What factors contribute to low PIFR
/ph/respiratory/spiolto/expert-videos/dr-omar-usmaniwhat-are-important-considerations-while-selecting

14:45
Dr. Omar Usmani_What are the important considerations while selecting an inhaler for a COPD Patient
/ph/respiratory/spiolto/respimat/how-use-video-respimat

1:43
How to Use Video for Respimat Device
/ph/respiratory/spiolto/respimat/how-use-video-respimat-device

3:19
How to Use Video for Respimat Device
/ph/respiratory/spiolto/quality-life/copd-spiolto-microlearning-physical-activity-philippines

08:57
COPD SPIOLTO MICROLEARNING PHYSICAL ACTIVITY Philippines
/ph/respiratory/spiolto/quality-life/copd-otivato-primary-manuscript-video-abstract-philippines

02:51
COPD OTIVATO Primary Manuscript Video Abstract Philippines
/ph/respiratory/spiolto/inhaleability/copd-spiolto-microlearning-inspiratory-flow-philippines

09:01
COPD SPIOLTO MICROLEARNING INSPIRATORY FLOW Philippines
/ph/respiratory/spiolto/expert-videos/matching-inhaler-patient-inhalation-effort

49:02
Matching the Inhaler to the Patient Inhalation Effort and Patient Needs
/ph/respiratory/spiolto/expert-videos/spiolto-respimat-demonstration

03:20
SPIOLTO® RESPIMAT® Demonstration
/ph/respiratory/spiolto/quality-life/expert-perspective-otivacto-real-world-evidence

02:54
Expert's Perspective on OTIVACTO Real World Evidence
/ph/respiratory/spiolto/quality-life/otivacto-real-world-evidence-improvement

02:42
OTIVACTO - Real World evidence on improvement in Physical Activity with LAMA/LABA
/ph/respiratory/spiolto/respimat/respimat-delivers-drug-deep-patient-lungs

02:53
Respimat® delivers drug deep into the patient's lungs without the need for forceful inhalation
/ph/respiratory/spiolto/respimat/52-copd-patients-have-suboptimal-peak-inspiratory-flow

01:55
52% of COPD patients have suboptimal Peak Inspiratory Flow (sPIF)
/ph/respiratory/spiolto/respimat/respimat-innovation-boehringer-ingelheim

01:59
Respimat® is an innovation from Boehringer Ingelheim and is the only Soft Mist Inhaler in the market
/ph/respiratory/spiolto/respimat/respimat-delivers-drug-actively-without-need-copd

03:29
Respimat® delivers drug actively without the need of COPD patients to forcefully inhale
/ph/respiratory/spiolto/respimat/thank-you-all-who-participated-2019-respeedmat-challenge

Thank you to all who participated in the 2019 ReSpeedMat Challenge!
/ph/respiratory/spiolto/efficacy/dynagito-key-conclusions

05:05
Dynagito® key conclusions
/ph/respiratory/spiolto/respimat/effortless-inhalation-matters

01:17
Effortless inhalation matters
/ph/respiratory/spiolto/respimat/how-use

00:51
Preparing Respimat® for Daily Use
/ph/respiratory/spiolto/efficacy/spiolto-respimat-improves-exercise-endurance-time

01:26
Tiotropium + Olodaterol (SPIOLTO® RESPIMAT®) improves exercise endurance time
/ph/respiratory/spiolto/efficacy/treatment-lamalaba-vs-lamalabaics

02:02
WISDOM trial suggests only a minority of COPD patients benefit from the addition of an ICS on top of SPIRIVA+LABA, and these are clearly identifiable
/ph/respiratory/spiolto/efficacy/early-intervention-optimize-lung-function

02:13
Early intervention to optimize lung function
/ph/respiratory/spiolto/prescribing-information

Tiotropium + olodaterol (Spiolto® Respimat®) Prescribing Information